Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials
- 13 August 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (4) , 2335-2343
Abstract
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. Though, corticosteroids are the cornerstone of therapy, the Janus kinase inhibitor abrocitinib has shown promise in recent ...Keywords
This publication has 26 references indexed in Scilit:
- Monoclonal antibodies for the treatment of atopic dermatitisCurrent Opinion in Allergy and Clinical Immunology, 2018
- Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysisJournal of Dermatological Science, 2018
- The Economics Burden of Atopic Dermatitis2017
- Atopic Dermatitis: Pathophysiology2017
- Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelinesJournal of Allergy and Clinical Immunology, 2017
- A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standardsJournal of the American Academy of Dermatology, 2016
- Atopic Dermatitis: Global Epidemiology and Risk FactorsAnnals of Nutrition and Metabolism, 2015
- Atopic Dermatitis: Natural History, Diagnosis, and TreatmentISRN Allergy, 2014
- Health Outcome Measures in Atopic Dermatitis: A Systematic Review of Trends in Disease Severity and Quality-of-Life Instruments 1985–2010PLOS ONE, 2011
- Topical treatment of atopic dermatitisImmunology and Allergy Clinics of North America, 2004